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RESEARCH ARTICLE
Evaluation of No Evidence of Progression
or Active Disease (NEPAD) in Patients
With Primary Progressive Multiple
Sclerosis in the ORATORIO Trial
Jerry S. Wolinsky, MD,1 Xavier Montalban, MD, PhD,2,3 Stephen L. Hauser, MD,4
Gavin Giovannoni, MBBCh, PhD, FCP,5 Patrick Vermersch, MD, PhD,6
Corrado Bernasconi, MD, PhD,7 Gurpreet Deol-Bhullar, BS,7 Hideki Garren, MD, PhD,8
Peter Chin, MD, MSHS,8 Shibeshih Belachew, MD, PhD,7 and Ludwig Kappos, MD9
Objective: No evidence of progression or active disease (NEPAD) is a novel combined endpoint defined by the
absence of both progression and inflammatory disease activity in primary progressive multiple sclerosis (PPMS). In the
placebo-controlled phase III ORATORIO study (NCT01194570), we investigated the effect of ocrelizumab on this com-
prehensive outcome and its components in a post-hoc analysis.
Methods: The proportion of patients with NEPAD (no evidence of progression [NEP; no 12-week confirmed progres-
sion of ≥1/≥0.5 points on the Expanded Disability Status Scale if the baseline score was ≤5.5/>5.5 points, respectively;
no 12-week confirmed progression of ≥20% on the Timed 25-Foot Walk test and 9-Hole Peg Test], no brain magnetic
resonance imaging activity [no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions], and no protocol-
defined relapse) from baseline to week 120 was determined in ocrelizumab- (600 mg; n = 465) and placebo-treated
(n = 234) patients.
Results: The majority of ORATORIO study patients with PPMS experienced clinical progression or evidence of disease
activity. From baseline to week 120, 29.9% and 42.7% ocrelizumab-treated compared to 9.4% and 29.1% placebo-
treated patients maintained NEPAD (relative risk [95% confidence interval {CI}], 3.15 [2.07–4.79]; p < 0.001) and NEP
(relative risk [95% CI], 1.47 [1.17–1.84]; p < 0.001), respectively. Effects on the individual components of both measures
were consistent with the compound outcomes.
Interpretation: Compared to placebo, ocrelizumab enhanced 3-fold the proportion of PPMS patients with no evidence
of either progression or inflammatory disease activity. NEPAD may represent a sensitive and meaningful comprehen-
sive measure of disease control in patients with PPMS.
ANN NEUROL 2018;84:527–536
Primary progressive multiple sclerosis (PPMS) is charac-terized by insidiously increasing neurological disability
from disease onset, with or without temporary plateaus in
progression and with or without superimposed relapses.1
Preventing progression is an essential treatment goal in
PPMS, a goal that drugs tested in previous clinical studies
failed to achieve.2–4 Ascertaining the absence of progres-
sion in both clinical trials and clinical practice requires
reliable and comprehensive measures of disease progres-
sion. Although widely used,5,6 the Expanded Disability
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Status Scale (EDSS) has limited ability to reliably capture
change in functioning in a range of domains, notably
ambulation speed and hand/arm function, which are
major contributors to the overall disability burden in
patients with progressive multiple sclerosis (MS). No evi-
dence of progression (NEP) is an endpoint that measures
absence of disability progression beyond the limits of
EDSS as a standalone, including upper limb function and
ambulation speed. Maintaining NEP status (Fig 1) reflects
stable clinically apparent disease with no worsening in
three major measures of MS disability: EDSS, ambulation
assessed by the Timed 25-Foot Walk (T25FW) test, and
upper limb function assessed by the 9-Hole Peg Test
(9HPT), although clinical and magnetic resonance imag-
ing (MRI) measures of acute disease activity are not
captured.
In PPMS, signs of acute disease activity, as defined
by relapses, T1 gadolinium (Gd)-enhancing lesions, and
new or enlarging T2 hyperintense lesions on brain MRI,
are present but less frequent than in relapse-onset MS.7
With “no evidence of progression or active disease”
(NEPAD), we propose a novel endpoint that assesses the
combined absence of three measures of disability progres-
sion (NEP) and clinical and MRI measures of active dis-
ease (Fig 1). NEPAD may represent a more sensitive and
comprehensive measure of disease control in patients
with PPMS.
Ocrelizumab is a recombinant, humanized monoclo-
nal antibody that selectively depletes CD20-expressing B
cells,8,9 B lymphocytes being a significant contributor to
the pathogenesis of MS.10,11 The randomized, double-
blind, placebo-controlled phase III trial, ORATORIO,
evaluated the efficacy and safety of ocrelizumab in patients
with PPMS and demonstrated superior efficacy of ocreli-
zumab on the primary endpoint, time-to-onset of
12-week confirmed disability progression (CDP), as mea-
sured by the EDSS.12 Based on such results, ocrelizumab
is the first disease-modifying therapy approved for
PPMS.13,14
The objective of the current analyses was to assess
the effect of ocrelizumab on NEP and NEPAD and their
components, two novel, more comprehensive and sensitive
outcome measures for patients with PPMS in the ORA-
TORIO trial.
Patients and Methods
Trial Design and Patients
ORATORIO was a phase III, randomized, placebo-con-
trolled, double-blind, multicenter trial (NCT01194570);
details have been reported previously.12 Key eligibility cri-
teria included age of 18 to 55 years, diagnosis of PPMS
(2005 revised McDonald criteria),15 and an EDSS score
of 3.0 to 6.5 at screening. All patients were required to
have a documented history, or the presence at screening,
of an elevated immunoglobulin G (IgG) index or at least
one IgG oligoclonal band detected in the cerebrospinal
fluid, and no history of previous clinical relapse. Patients
(n = 732) were randomized (2:1) to receive either ocreli-
zumab 600mg by intravenous (IV) infusion every 24 weeks
or placebo every 24 weeks for ≥ 120 weeks.12 Randomiza-
tion was stratified by region (USA versus rest of world
[ROW]) and age (≤45 versus > 45 years).
Clinical and MRI Endpoints
Prespecified Outcome Measures. CDP was defined as a
≥1-point increase in EDSS score from a baseline EDSS
score ≤5.5, or a 0.5-point increase in EDSS score from a
baseline EDSS score >5.5, sustained for at least
12 weeks.12 Protocol-defined relapses were new or worsen-
ing neurological symptoms attributable to MS that lasted
longer than 24 hours; were preceded by neurological sta-
bility for at least 30 days; and were accompanied by wors-
ening on examination reflected as ≥0.5-step increase from
previous EDSS score or ≥2-point increase in one qualify-
ing Functional Systems Score (FSS), or 1-point increase in
two or more qualifying FSSs.12 Brain MRI was performed
at baseline and weeks 24, 48, and 120; new or enlarging
T2 lesions and/or T1 Gd-enhancing lesions on any post-
baseline scan were considered evidence of MRI disease
activity.
NEP and NEPAD
NEP status was defined as the absence of 12-week con-
firmed clinical progression, as measured by: no 12-week
CDP on EDSS, no 12-week confirmed ≥ 20% progression
FIGURE 1: Clinical and subclinical components of NEPAD. No
Evidence of Progression defined as: no 12-week CDP, as
measured by the EDSS; no evidence of 12-week
confirmed ≥ 20% progression on hand/arm function as
measured by 9HPT; no evidence of 12-week confirmed
≥ 20% progression on ambulation as measured by the
T25FW test. 9HPT = 9-Hole Peg Test; CDP = confirmed
disability progression; EDSS = Expanded Disability Status
Scale; Gd+ = gadolinium-enhancing; MRI = magnetic resonance
imaging; NEPAD = no evidence of progression or active
disease; T25FW = Timed 25-Foot Walk.
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on hand/arm function as measured by the 9HPT, and no
12-week confirmed ≥ 20% progression on ambulation as
measured by the T25FW test. The 20% cutoff for progres-
sion on the T25FW test and the 9HPT has previously been
shown to be a clinically meaningful magnitude of disease
progression.16 NEPAD was defined as: NEP, no brain
MRI-measured disease activity (no new or enlarging T2
lesions and no T1 Gd-enhancing lesions), and no protocol-
defined relapses (NEP and NEPAD summarized in Fig 1).
The schedule of MRI scans and the assessment of disability
measures, including EDSS score, T25FW, and 9HPT, are
shown in Figure 2.
Statistical Analyses
The exploratory post-hoc analysis of the proportion of
patients with NEP and NEPAD encompassed the period
from baseline to week 120, which represents the mini-
mum duration of the double-blind phase for individual
patients in the event-driven ORATORIO study. The
NEP analysis population (230 placebo- and 461 ocrelizu-
mab-treated patients), hereafter termed modified
intention-to-treat (mITT)-NEP population, was the ITT
population excluding patients with missing baseline score
for EDSS, T25FW, or 9HPT, or withdrawn for reasons
other than lack of efficacy or death preceding the week
120 visit without evidence of progression (EP) before
withdrawal (n = 41). Applying the same exclusion criteria,
234 placebo- and 465 ocrelizumab-treated patients were
evaluable from baseline to week 120 (excluded patients,
n = 33) in the mITT-NEPAD analysis population.
Patients withdrawn from treatment preceding the week
120 visit because of lack of efficacy or death were imputed
as having EP or evidence of progression or active disease
(EPAD), in respective analysis of NEP and NEPAD.
Sensitivity analyses were also conducted in the ITT
population where patients excluded from the mITT-
NEPAD population were imputed as having NEPAD
(“best outcome scenario”) or EPAD (“worst outcome sce-
nario”). Based on previous evidence that sex may influence
the rate of progression in PPMS,2 an additional explor-
atory subgroup analysis of NEPAD by sex was also con-
ducted. NEP and NEPAD data are presented using a
Venn diagram surface-proportional representation. NEP,
NEPAD, and the respective components were compared
in patients treated with ocrelizumab with those receiving
placebo using the Cochran–Mantel–Haenszel test strati-
fied by age (≤45 versus > 45 years) and region (USA ver-
sus ROW).
Results
Baseline Demographics and Disease
Characteristics
All major baseline demographics and characteristics were
balanced between treatment groups in the mITT-NEPAD
and mITT-NEP analysis populations (Supplementary
Table S1). When patients were categorized by EP/NEP or
EPAD/NEPAD status over 120 weeks, baseline demo-
graphics and disease characteristics were similar. However,
compared to patients with EP or EPAD, patients who
maintained NEP or NEPAD over 120 weeks had lower T2
lesion volume and EDSS score at baseline and slightly bet-
ter baseline functional performance as assessed by the
FIGURE 2: Schedule of MRI scans and assessment of disability measures in the ORATORIO trial. aThe blinded treatment period
continued until the last patient completed at least 120 weeks and a target of 253 CDP events was reached. bPatients received
methylprednisolone before each ocrelizumab infusion or placebo infusion. c2:1 ocrelizumab:placebo randomization stratified by
age (<45 vs > 45 years) and region (USA vs rest of world). dPatients who declined to participate in the OLE entered safety
follow-up. eContinued monitoring occurred if B cells were not repleted. BL = baseline; CDP = confirmed disability progression;
IV = intravenous; MRI = magnetic resonance imaging; OLE = open-label extension.
October 2018 529
Wolinsky et al: NEPAD in Primary Progressive Multiple Sclerosis
T25FW test, 9HPT, and the Paced Auditory Serial Addi-
tion Test scores (Supplementary Tables S2 and S3). In
addition, patients who maintained NEPAD also had a
lower number of T1 Gd-enhancing lesions at baseline com-
pared to patients with EPAD (Supplementary Table S3).
Proportions of Patients With NEP
In the mITT-NEP analysis population, ocrelizumab treat-
ment increased the proportion of patients with PPMS
maintaining NEP from baseline to week 120 by 47%
compared to placebo (ocrelizumab 47.2% versus placebo
29.9%; relative risk [95% confidence interval {CI}], 1.47
[1.17–1.84]; p < 0.001; Fig 3).17 This was also reflected
in superiority of ocrelizumab compared to placebo across
the individual components of NEP from baseline to week
120 (no confirmed ≥ 20% progression on T25FW,
p = 0.002; no confirmed ≥ 20% progression on 9HPT,
p = 0.001), although significance was not reached for
CDP on EDSS (p = 0.14; the lower effect size and lack of
significance compared to ORATORIO primary end-
point12 may be explained by differences in the analysis
population, statistical methods used, and exposure dura-
tion, ie, NEP assessment ends at week 120 whereas the
primary endpoint was a time-to-event analysis based on
the totality of the event-driven study duration). In addi-
tion, compared to placebo, ocrelizumab increased the pro-
portion of patients with no progression on all pairwise
combinations of NEP components assessed: no 12-week
confirmed progression on EDSS and no 12-week con-
firmed ≥ 20% progression on T25FW (p < 0.001); no
12-week confirmed progression on EDSS and no 12-week
confirmed ≥ 20% progression on 9HPT (p = 0.050), and
no 12-week confirmed ≥ 20% progression on T25FW
and on 9HPT (p = 0.002; Table 2).
Proportions of Patients With NEPAD
In the mITT-NEPAD analysis population, 91% of
patients in the placebo group experienced clinical progres-
sion or active disease (EPAD) from baseline to week
120, which was principally attributed to the occurrence of
MRI features characteristic of new inflammatory activity.
Ocrelizumab treatment increased by 3-fold the proportion
of patients with NEPAD from baseline to week 120 com-
pared to placebo (ocrelizumab 29.9% versus placebo
9.4%; relative risk [95% CI], 3.15 [2.07–4.79];
p < 0.001; Fig 4). This was reflected in numerical superi-
ority across all the individual components of NEPAD with
ocrelizumab compared to placebo from baseline to week
120, where ocrelizumab increased the proportion of
patients with NEP, no MRI-measured disease activity,
including no new or enlarging T2 lesions and no T1 Gd-
enhancing lesions, and no protocol-defined relapse
(Table 1). Ocrelizumab also significantly increased the
proportion of patients with pairwise components of
NEPAD at week 120 compared to placebo: NEP and no
MRI-measured disease activity; NEP and no protocol-
defined relapse; and no protocol-defined relapse and no
MRI-measured disease activity compared to placebo
(Table 2).
Sensitivity analyses performed in the ITT population
(excluding 1 patient with missing baseline EDSS, follow-
ing the approach originally used in the primary endpoint
analysis),12 with imputation for patients who withdrew
early for reasons other than “lack of efficacy” or “death”
and who had NEPAD at time of study treatment discon-
tinuation, were consistent with the main results
(Supplementary Table S4). This was true both for
NEPAD imputation of early discontinuers (“best outcome
scenario”: ocrelizumab 33.5% versus placebo 13.1%;
FIGURE 3: Proportion of patients with NEP from baseline to week 120 in ORATORIO. Venn diagram with approximately surface-
proportional representation. Exploratory analysis; p value from a Cochran–Mantel–Haenszel test stratified by age (≤45
vs > 45 years) and region (USA vs rest of world). NEP analysis population is ITT population excluding patients with missing
baseline score for EDSS, T25FW, or 9HPT, or withdrawn for reasons other than efficacy failure or death preceding the week
120 visit, and without evidence of progression (n = 41). Imputation is used for patients withdrawn from the treatment prior to
the week 120 visit and who had no event; patients withdrawn because of efficacy failure or death are considered as having an
event. Relative risk for ocrelizumab vs placebo. 9HPT = 9-Hole Peg Test; CI = confidence interval; EDSS = Expanded Disability
Status Scale; ITT = intention-to-treat; NEP = no evidence of progression; T25FW = Timed 25-Foot Walk.
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relative risk [95% CI]: 2.55 [1.80–3.60]; p < 0.001) and
EPAD imputation of early discontinuers (“worst outcome
scenario”: ocrelizumab 28.8% versus placebo 9.0%; rela-
tive risk [95% CI]: 3.17 [2.08–4.83]; p < 0.001).
Additional sensitivity analyses of NEPAD from base-
line to week 120 where NEP components were based on
24-week instead of 12-week confirmed clinical progression
events was also consistent with the main results
(Supplementary Table S5) as was an analysis of NEPAD
using an alternative time-to-event Kaplan–Meier approach
over the totality of ORATORIO study duration (Fig 5;
Supplementary Table S6).
Exploratory analyses of NEPAD by sex were also
consistent with the primary results. Compared to placebo,
ocrelizumab significantly increased the proportion of
patients with NEPAD for both male and female patients
(male, p < 0.001; female, p < 0.001; Table 1). This was
reflected in numerical superiority across all the individual
components of NEPAD in male and female patients with
ocrelizumab compared to placebo from baseline to week
120, except for no 12-week confirmed progression on
EDSS where proportions were similar in both groups for
female patients (Table 1). In addition, there was no evi-
dence for the heterogeneity of the treatment effect in rela-
tion to sex (p > 0.5 for the treatment-by-sex interaction in
logistic regression models for NEPAD and its three com-
ponents with adjustments for age, region, disease duration,
baseline values of the T25FW test and 9HPT, and pres-
ence of T1 Gd-enhancing lesions at baseline). Further
exploratory subgroup analyses were performed by age at
study baseline. Proportions of patients with NEPAD from
baseline to week 120 were significantly higher in
ocrelizumab-treated patients compared to the placebo
group, both in younger patients (age at study baseline
≤45 years): ocrelizumab 28.9% versus placebo 5.4%; rela-
tive risk [95% CI]: 5.24 [2.35–11·69]; (p < 0.001), and
older patients (age at study baseline >45 years): ocrelizu-
mab 30.8% versus placebo 13.1%; relative risk [95% CI]:
2.34 [1.42–3.84]; (p < 0.001). The numerically lower
magnitude of ocrelizumab treatment effect on NEPAD in
the older subgroup appeared to be, in part, driven by the
differential behavior of the placebo group where twice as
many of the older patients experienced NEPAD compared
to the younger subgroup (Supplementary Table S7).
There was no statistical evidence for a treatment effect
heterogeneity on NEPAD combined outcome (p = 0.18
for the treatment-by-age group interaction in the model as
described above).
Discussion
In this post-hoc analysis of the phase III ORATORIO
study, ocrelizumab increased the proportion of patients
with PPMS maintaining NEP and NEPAD status com-
pared to placebo, which is consistent with ocrelizumab
efficacy on the primary and secondary endpoints in this
trial.12
NEP may represent a more comprehensive clinical
trial outcome for patients with PPMS, given that the
Venn diagram representation of NEP components illus-
trates that the three outcome measures capture substantial
nonoverlapping domains of MS disability burden. In the
placebo arm of ORATORIO, more than half of patients
with PPMS who had no confirmed disability progression,
FIGURE 4: Proportion of patients with NEPAD from baseline to week 120 in ORATORIO. Exploratory analysis; the relative risk
and p value are from a Cochran–Mantel–Haenszel test stratified by age (≤45 vs > 45 years) and region (USA vs rest of world).
NEPAD analysis population is a modified ITT population. Patients who discontinued treatment early with at least one event
before discontinuation were considered as having EPAD. Patients with no reported event before early discontinuation were
considered as having EPAD if the reason for early treatment discontinuation was reported to be lack of efficacy or death;
otherwise, they were excluded from the analysis. In this approximately surface-proportional Venn diagram representation, the
sector including two ocrelizumab patients with protocol-defined relapse but with no MRI activity and NEP cannot be displayed.
Relative risk for ocrelizumab vs placebo. CI = confidence interval; EPAD = evidence of progression or active disease;
Gd+ = gadolinium-enhancing; ITT = intention-to-treat; MRI = magnetic resonance imaging; NEP = no evidence of progression;
NEPAD = no evidence of progression or active disease.
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as measured by EDSS, experienced confirmed worsening
in ambulation when measured by the T25FW test. Simi-
larly, a sizeable proportion of patients who had no con-
firmed progression on EDSS, worsened on hand/arm
function, as assessed by 9HPT. Treatment with ocrelizu-
mab increased the proportion of patients with NEP at
120 weeks by 47% compared to placebo. A consolidated
demonstration of absence of worsening in ambulation
using the T25FW test in those patients who might have a
stable EDSS may be of utmost importance, given that
walking impairment negatively impacts employment
status, the ability to perform activities of daily living, and
health-related quality of life of patients with MS. 18,19
Furthermore, maintenance of walking ability has been
reported by patients with MS as the most highly valued
bodily function.20 In addition, given the asynchronous
disease course in progressive MS,21 a comprehensive ascer-
tainment of clinical stability should require confirmation
of the absence of progression on upper limb function, as
assessed by 9HPT, in patients stable on EDSS and the
T25FW test. Evaluation of NEP status may therefore rep-
resent a novel, clinically meaningful endpoint and a
TABLE 1. Proportion of Patients With NEPAD (and Its Individual Components) in the Complete mITT-NEPAD
Population, and in Male and Female Patients From Baseline to Week 120 in ORATORIO
mITT-NEPAD Population Male Female
Placebo
n = 234
Ocrelizumab
n = 465
Placebo
n = 117
Ocrelizumab
n = 241
Placebo
n = 117
Ocrelizumab
n = 224
NEPAD (mITT-NEPAD population), % (n) 9.4 (22) 29.9 (139) 7.7 (9) 29.9 (72) 11.1 (13) 29.9 (67)
Relative risk (95% CI) p value 3.15 (2.07–4.79) p < 0.001 3.73 (1.94–7.17) p < 0.001 2.70 (1.56–4.68) p < 0.001
No evidence of progression (NEP)a, % (n) 30.3 (71) 43.2 (201) 28.2 (33) 44.0 (106) 32.5 (38) 42.4 (95)
Relative risk (95% CI) p value 1.42 (1.14–1.77) p = 0.001 1.56 (1.13–2.16) p = 0.004 1.30 (0.96–1.76) p = 0.080
No 12-week confirmed progression on EDSS, %
(n)
63.7 (149) 68.8 (320) 59.0 (69) 70.5 (170) 68.4 (80) 67.0 (150)
Relative risk (95% CI) p value 1.08 (0.97–1.21) p = 0.16 1.19 (1.00–1.42) p = 0.035 0.98 (0.84–1.14) p = 0.79
No 12-week confirmed ≥ 20% progression on
T25FW, % (n)
39.7 (93) 51.4 (239) 36.8 (43) 51.0 (123) 42.7 (50) 51.8 (116)
Relative risk (95% CI) p value 1.29 (1.08–1.55) p = 0.004 1.38 (1.06–1.81) p = 0.012 1.20 (0.94–1.54) p = 0.13
No 12-week confirmed ≥ 20% progression on
9HPT, % (n)
71.8 (168) 82.4 (383) 68.4 (80) 80.5 (194) 75.2 (88) 84.4 (189)
Relative risk (95% CI) p value 1.14 (1.04–1.25) p = 0.002 1.17 (1.02–1.34) p = 0.015 1.12 (1.00–1.26) p = 0.037
No evidence of brain MRI-measured disease
activity, % (n)
26.5 (62) 70.3 (327) 23.9 (28) 68.5 (165) 29.1 (34) 72.3 (162)
Relative risk (95% CI) p value 2.64 (2.12–3.28) p < 0.001 2.75 (1.98–3.83) p < 0.001 2.51 (1.87–3.38) p < 0.001
No new or enlarging T2 lesions, % (n) 26.5 (62) 70.5 (328) 23.9 (28) 68.9 (166) 29.1 (34) 72.3 (162)
Relative risk (95% CI) p value 2.64 (2.12–3.29) p < 0.001 2.77 (1.99–3.85) p < 0.001 2.51 (1.87–3.38) p < 0.001
No T1 Gd-enhancing lesions, % (n) 58.1 (136) 93.3 (434) 57.3 (67) 93.0 (224) 59.0 (69) 93.8 (210)
Relative risk (95% CI) p value 1.60 (1.43–1.79) p < 0.001 1.60 (1.37–1.88) p < 0.001 1.60 (1.37–1.87) p < 0.001
No protocol-defined relapses, % (n) 82.9 (194) 92.7 (431) 80.3 (94) 92.1 (222) 85.5 (100) 93.3 (209)
Relative risk (95% CI) p value 1.12 (1.05–1.19) p < 0.001 1.14 (1.04–1.26) p = 0.001 1.09 (1.01–1.19) p = 0.018
Relative risk for ocrelizumab versus placebo.
aMinor differences in NEP component numbers (when NEP was herein analyzed in the mITT-NEPAD population) compared to those presented in
Figure 3 (mITT-NEP population) originate from the differences between mITT-NEP and mITT-NEPAD population sample size, as outlined in Sup-
plementary Table S1.
9HPT = 9-Hole Peg Test; CI = confidence interval; EDSS = Expanded Disability Status Scale; Gd = gadolinium; mITT = modified intention-to-
treat; MRI = magnetic resonance imaging; NEP = no evidence of progression; NEPAD = no evidence of progression or active disease;
T25FW = Timed 25-Foot Walk.
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pragmatic goal in the management of patients with PPMS
in clinical practice.
NEPAD is an extension of NEP incorporating
relapses, new or enlarging T2 lesions, and T1 Gd-
enhancing lesions, which are the inflammatory disease
activity descriptors of progressive MS phenotypes.22 On
this composite outcome that includes all descriptors of
progressive disease as per the Lublin et al (2014) revised
consensus on MS disease course definitions,22 the propor-
tion of patients with NEPAD was 3-fold higher with ocre-
lizumab compared to placebo. Sensitivity analyses with
opposite imputation of missing data confirmed the robust-
ness of the primary findings. NEPAD can also be viewed
as an extension of NEDA (no evidence of disease
activity),23 integrating aspects of disability burden (hand/
arm function and ambulation impairment), which are
important aspects of the clinical course of progressive
MS.22 Notwithstanding this integration of two additional
clinical components, the relative importance of MRI activ-
ity components remains dominant in the determination of
NEPAD outcome as commonly observed for NEDA
analyses24–26 in patients with relapsing multiple sclerosis
(RMS). Although NEDA is increasingly seen as a treat-
ment goal, and some long-term data support the
prognostic value of NEDA for predicting future disability
progression in patients with RMS with high efficacy
therapies,24–26 similar analyses are warranted to investigate
the prognostic utility of NEPAD in progressive MS popu-
lations. In particular, the added value of MRI components
of NEPAD for predicting long-term outcomes remains
unknown in patients with PPMS.
Similar proportions of male and female patients with
PPMS maintained NEPAD status with significantly
greater proportions in the ocrelizumab-treated group com-
pared to placebo within each sex subgroup. Except for
12-week confirmed disability progression on EDSS, a
numerical superiority favoring ocrelizumab was observed
across all individual components of NEP and NEPAD to
a similar extent in male and female patients. When
patients were analyzed in subgroups by age at study base-
line, significantly greater proportions of patients with
NEPAD were observed in the ocrelizumab-treated group
compared to placebo within each age subgroup. The
higher effect of ocrelizumab on NEPAD outcome noted
in younger patients appeared to reflect, in part, age-related
differences in the behavior of the placebo group.
PPMS patients with NEP or NEPAD versus those
with evidence of progression or active disease did not
TABLE 2. Proportion of Patients With Pairwise Components of NEP and NEPAD From Baseline to Week 120 in
ORATORIO
Pairwise Components of NEP
(mITT-NEP population), % (n)
Placebo
n = 230
Ocrelizumab
n = 461
Relative Risk
(95% CI) p
No 12-week confirmed progression on EDSS and
no 12-week confirmed ≥ 20% progression on T25FW
31.3 (72) 44.7 (206) 1.43
(1.15–1.78)
<0.001
No 12-week confirmed progression on EDSS and
no 12-week confirmed ≥ 20% progression on 9HPT
53.5 (123) 61.4 (283) 1.15
(0.99–1.32)
0.05
No 12-week confirmed ≥ 20% progression on
T25FW and on 9HPT
36.1 (83) 48.4 (223) 1.34
(1.10–1.63)
0.002
Pairwise Components of NEPAD
(mITT-NEPAD population), % (n)
Placebo
n = 234
Ocrelizumab
n = 465
Relative Risk
(95% CI) p
No NEP and no brain MRI-measured disease activity 9.4 (22) 30.3 (141) 3.19
(2.10–4.85)
<0.001
No NEP and no protocol-defined relapses 29.9 (70) 42.2 (196) 1.41
(1.13–1.76)
0.002
No protocol-defined relapses and
no brain MRI-measured disease activity
25.2 (59) 68.0 (316) 2.68
(2.13–3.36)
<0.001
Relative risk for ocrelizumab versus placebo.
9HPT = 9-Hole Peg Test; CI = confidence interval; EDSS = Expanded Disability Status Scale; mITT = modified intention-to-treat; MRI = magnetic
resonance imaging; NEP = no evidence of progression; NEPAD = no evidence of progression or active disease; T25FW = Timed 25-Foot Walk.
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differ in age, MS disease duration, or normalized brain
volume at baseline, whereas patients with NEP or
NEPAD had a lower total lesion burden and disability at
baseline. Whether such imbalances may reflect objective
differences between those baseline covariates as potential
prognostic factors for NEP/NEPAD in patients with
PPMS remains to be explored.
In conclusion, ocrelizumab increased the proportion
of patients with PPMS with no evidence of progression
and no clinical and subclinical disease activity compared
to placebo. As such, NEPAD may represent a meaningful
and comprehensive disease outcome in patients with
PPMS. Keeping in mind that this analysis was post hoc
and not adjusted for multiplicity testing, further valida-
tion of the clinical utility of NEPAD beyond the ORA-
TORIO results should be sought by similar analyses in
other primary and secondary progressive MS study popu-
lations. In RMS, NEPAD status was recently evaluated in
the pooled OPERA I and OPERA II studies, with similar
findings favoring ocrelizumab compared to interferon
beta-1a.27
NEPAD represents the first incremental step of adap-
tation of NEDA to more comprehensively capture the dif-
ferent facets of progression. It is a reasonable assumption
that in the specific intent of ascertaining the complete
absence/remission of any measurable “signs of disease
activity/progression,” the NEPAD combined endpoint may
outperform any of its individual components. Subsequent
evolution of the NEPAD measure may include the integra-
tion of cognitive and visual performance outcomes such as
the symbol-digit modalities test or low-contrast letter acu-
ity, respectively. Chronic T2 lesions with evolving T1
hypointensity may also be considered as a readout for per-
manent tissue damage accumulation, as well as whole-brain
volume loss, where more research is needed to discriminate
pathological atrophy from normal aging or noise of the
measurement, and determine personalized thresholds of
annualized rates of brain volume change.28–30
FIGURE 5: Kaplan–Meier analysis of time to evidence of progression or active disease in the ITT population during the double-
blind controlled period in ORATORIO. Patients are considered as failing NEPAD if one of the following events occurred:
protocol-defined relapse, 12-week CDP, 12-week confirmed progression on T25FW or 9HPT, or MRI activity. Hazard ratio
estimates are obtained from a Cox model stratified by region (ROW; US) and including age, disease duration from onset,
baseline EDSS score, baseline T25FW, and baseline 9HPT. p value is from a log-rank test stratified by region (ROW; US), age
(>45; ≤ 45 years), and baseline EDSS score category (<4; ≥ 4). 9HPT = 9-Hole Peg Test; CDP = confirmed disability progression;
CI = confidence internal; EDSS = Expanded Disability Status Scale; ITT = intention-to-treat; MRI = magnetic resonance imaging;
NEPAD = no evidence of progression or active disease; ROW = rest of world; T25FW = Timed 25-Foot Walk.
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Future analyses, including data from the open-label
extension of the ORATORIO study and real-world evi-
dence, will determine whether NEPAD maintained
throughout 120 weeks will translate into sustained
NEPAD and enhanced protection against accrual of dis-
ability in patients with PPMS over the long term.
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